Evotec video interesting19 May 2020 14:49
Creating a collaborative toolbox to fight COVID-19
Guest: Dr. Werner Lanthaler, CEO, Evotec
In this episode of Conversations in Healthcare, Mike Ward talks to Werner Lanthaler, CEO of Evotec, about how COVID-19 is bringing pharma leaders together and giving them collaborative momentum. Dr. Lanthaler is a co-founding member of COVID R&D, a global pharma industry initiative that has come together to rapidly respond to the pandemic. Together they are fast-tracking learnings and protocols to create a toolbox that can accelerate activities like clinical trials, re-purposing compounds and data sharing to address the crisis faster. COVID-19 has brought barriers down and truly brought the healthcare industry together, but could this forced synergy and learning be used to accelerate treatment creation in the future?
About our Guest
Dr. Werner Lanthaler, CEO, Evotec
Dr. Werner Lanthaler was appointed Chief Executive Officer of Evotec in March 2009. From March 2000 to March 2009 he was Chief Financial Officer at Intercell AG. During his tenure, Intercell developed from a venture-backed biotechnology company into a global vaccine player. Dr. Lanthaler played a pivotal role in many of the company's major corporate milestones including the product approval of Intercell's Japanese Encephalitis Vaccine, the company's acquisitions and strategic pharma partnerships, as well as the company's Initial Public Offering in 2005. Dr. Lanthaler is also a co-founding member of ACTIV, a public-private partnership aiming to develop a framework to rapidly respond to COVID-19 and future pandemics.